Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: SVT-40776

Latest Information Update: 30 Jul 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SALVAT
  • Developer Kwang Dong Pharmaceutical; SALVAT
  • Class Antispasmodics; Quinuclidines
  • Mechanism of Action Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Overactive bladder

Highest Development Phases

  • No development reported Overactive bladder

Most Recent Events

  • 30 Jul 2015 No recent reports on development identified - Phase-II for Overactive bladder in USA, Australia, Czech Republic, Germany, Hungary, Netherlands, New Zealand, Russia, South Africa, South Korea and Spain (PO)
  • 09 Apr 2013 Efficacy and adverse events data from a phase IIb trial in Overactive bladder in South Korea released by SALVAT and Kwang Dong
  • 09 Apr 2013 SALVAT and Kwang Dong complete a phase IIb trial in Overactive bladder in South Korea (NCT01458197)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top